HomeFDA

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

The US Food and Drug Administration (FDA) has granted 4SC’s application for Orphan Drug Designation for resminostat (Kinselby) for cutaneous T cell lymphoma (CTCL). Marketing Authorisation Application (MAA) for Kinselby (resminostat) in the EU remains on track for filing in Q1 2024.

4SC AG (4SC, FSE Prime Standard: VSC) received notification that the US Food and Drug Administration (FDA) has granted 4SC’s application for Orphan Drug Designation for resminostat (Kinselby) for cutaneous T cell lymphoma (CTCL).

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Source4SC AG
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Graphene Nanotubes Revolutionize Protective Film Technology: Ultrathin, Permanently Conductive PSA

OCSiAl’s exceptional graphene nanotubes -based solution addresses these issues, ushering in a new era of silicone PSA technology. The user-friendly nanotube dispersion TUBALLTM MATRIX 617 results in excellent electrical conductivity combined with more than 90% transparency in a wide range of peeling-strength PSA films.

Optibrium’s Quantum Mechanics and Machine Learning Methods Predict Routes of Drug Metabolism

“Our latest study is the result of six years of focused research, delivering a practical model that allows users to predict metabolic pathways for a wide range of drug-like compounds. Thanks to our carefully curated datasets and our signature reactivity-accessibility approach, we have managed to build accurate isoform-specific regioselectivity models for the important Phase I and II enzyme families” Dr Mario Öeren, Principal Scientist, Optibrium said

Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for Early Skin Cancer Detection

The Nevisense System is a first-of-its-kind AI-driven technology that uniquely addresses the complexities of point-of-care detection of the deadliest form of skin cancer by providing clinicians with advanced analysis of irregular moles during routine skin checks.

Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics

"We are pleased to enter into this collaboration with Lycia Therapeutics, extending our service footprint to the area of extracellular protein degradation. We believe Lycia's leveraging of our antibody discovery capabilities will help accelerate its efforts to advance novel protein degrader therapeutics," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences said.

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent

Through this named patient program in the Netherlands ('Leveren op Artsenverklaring'), physicians may seek individual access to TLX250-CDx for use in PET characterisation of renal masses as ccRCC. The first patient was dosed at Radboud University Medical Centre in Nijmegen, Netherlands.
Load more

Medical Device News Magazine

Editorial Contact: mdnewsmagazine@infomeddnews.com

Medical Device News Magazine can help promote your medical devices, technologies, products or services. Advertising Contact: advmdn@infomeddnews.com

Telephone

© Copyright 2022 Medical Device News Magazine, is a division of PTM Healthcare Marketing, Inc

By using this website you agree to accept Medical Device News Magazine Privacy Policy